Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Tirzepatide in a Real-World CKD Cohort

A 62-person kidney-clinic cohort found lower weight, HbA1c and albuminuria after tirzepatide initiation, with stable eGFR during short follow-up.

Why we wrote this. A kidney-clinic cohort is relevant to practice but easy to overread as proof of renal protection. We separated the measured short-term changes from that larger claim.

In this article (5 sections)
  1. Who was included
  2. The metabolic findings
  3. The kidney findings
  4. Adverse events and monitoring limits
  5. What we do not yet know

A 2026 observational study followed 62 adults with chronic kidney disease, type 2 diabetes and obesity after they started tirzepatide. Over a median 21.4 weeks, median body weight, HbA1c and urinary albumin-to-creatinine ratio fell, while estimated glomerular filtration rate remained stable[1]. This was a real-world cohort without a control group, not a randomized trial.

The results describe what happened during treatment in one nephrology clinic. They cannot show that tirzepatide caused every change or that stable filtration means the medicine protects kidneys over the long term. Treatment selection, concurrent care and changes in other medicines may all have influenced the measurements.

Who was included

The multi-ethnic cohort included adults with chronic kidney disease stages 1 through 5 who initiated tirzepatide for type 2 diabetes with concurrent obesity. They were treated in a general nephrology clinic between June 2024 and October 2025[1]. Including stages 1 through 5 makes the group clinically broad, but the abstract does not report how many people were in each stage.

The researchers collected body weight, glycated haemoglobin (HbA1c), estimated glomerular filtration rate (eGFR), urinary albumin-to-creatinine ratio (uACR), blood pressure, lipids and insulin requirements. These measures answer different questions. eGFR estimates filtration, while uACR measures albumin leakage into urine. A change in one should not be presented as an identical change in the other.

The accessible PubMed abstract does not state the tirzepatide doses, assessment completeness, treatment discontinuations or changes to other glucose, blood pressure or kidney medicines. It also does not expose a prespecified primary endpoint. Those omissions limit any attempt to reconstruct the clinic's treatment pathway.

The metabolic findings

Median body weight decreased from 103 kg to 100 kg, with a reported p value below 0.0001. Median HbA1c fell from 63 mmol/mol (7.9%) to 54 mmol/mol (7.1%), with a p value of 0.002[1]. These are cohort-level before-and-after values rather than individual predictions.

The abstract also reports significant improvements in triglycerides, total cholesterol, LDL cholesterol and total daily insulin dose. It does not provide the numerical changes for those outcomes, so this readout does not estimate their size. Reduced insulin requirements may be clinically relevant, but the record does not show how insulin adjustments were decided or monitored.

Tirzepatide acts at GIP and GLP-1 receptors and is used for metabolic treatment in defined populations. Our tirzepatide evidence overview covers the broader evidence separately. This cohort is useful because it focuses on people seen in kidney practice, but it should not replace controlled evidence when estimating treatment effects.

The kidney findings

Median uACR declined from 111 mg/mmol to 44 mg/mmol, with a p value of 0.008. eGFR remained stable during follow-up[1]. Albuminuria is an important marker, yet a short-term decrease does not by itself prove prevention of kidney failure or slower long-term disease progression.

Stable eGFR is also a bounded finding because kidney function did not show an adverse average movement in the period described, but the abstract does not provide baseline and follow-up eGFR values, variability, slopes or stage-specific results. With 62 participants and roughly five months of median observation, uncommon harms and durable kidney outcomes remain unresolved.

The investigators describe the changes as clinically meaningful and say treatment in chronic kidney disease should be guided by a multidisciplinary team. That is an author conclusion from this cohort, not evidence that every person with kidney disease is an appropriate candidate. Eligibility, dosing and monitoring require individual clinical judgment.

Adverse events and monitoring limits

Gastrointestinal symptoms and decreased serum bicarbonate were the most common adverse events reported in the abstract[1]. The record does not provide event counts, severity, timing, discontinuations or a comparison rate. It therefore cannot quantify the chance of either event for a patient.

Lower serum bicarbonate can have several causes in people with chronic kidney disease. The abstract does not establish a mechanism or say that tirzepatide caused the decreases. It does, however, show why a real-world report should be read for both laboratory outcomes and tolerability rather than only for weight change.

What we do not yet know

There was no untreated or active-comparator group, no random assignment and no blinding, while people who remained under follow-up may differ from those who stopped treatment or lacked repeat tests. Regression to the mean, routine nephrology care and concurrent medication changes can all produce before-and-after differences in an uncontrolled cohort.

No PMCID is listed for the paper. The publisher page and direct PDF were blocked to scripted inspection, so this article stays within the PubMed abstract. We could not inspect full eligibility criteria, missing-data handling, subgroup analyses, funding, conflicts, exact follow-up completeness or the authors' full limitations.

People with chronic kidney disease should not change tirzepatide, insulin or other medicines from this report. Kidney stage, fluid status, gastrointestinal symptoms and glucose-lowering treatment can alter monitoring needs. Those decisions belong with the clinicians managing the person's diabetes and kidney disease.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute or facilitate the sale of any peptide product.

Frequently asked

Was this a randomized tirzepatide kidney trial?

No. It was an observational, uncontrolled cohort of 62 adults treated in a general nephrology clinic. It can describe changes during care but cannot prove that tirzepatide caused them.

What happened to albuminuria and eGFR?

Median urinary albumin-to-creatinine ratio fell from 111 to 44 mg/mmol, while eGFR remained stable over a median 21.4 weeks. The abstract does not provide eGFR values or long-term kidney outcomes.

What adverse events were reported?

Gastrointestinal symptoms and decreased serum bicarbonate were the most common adverse events named in the abstract. Counts, severity and discontinuation details were not exposed in the accessible record.

Sources

  1. [1]Carruthers JE et al. Real-world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide. Diabetic Medicine. 2026. PMID 42897718.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch record for Carruthers JE et al., PMID 42897718 (abstract, publication type and record-level identifiers).Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars